Needham & Company LLC Reiterates “Buy” Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $12.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s target price points to a potential upside of 135.29% from the stock’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $5.10 on Tuesday. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.96. The stock has a market capitalization of $1.05 billion, a P/E ratio of -4.77 and a beta of 1.96. The stock’s fifty day moving average is $4.89 and its 200 day moving average is $5.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to the consensus estimate of $85.62 million. During the same quarter in the previous year, the business posted ($0.28) EPS. The firm’s revenue for the quarter was up 34.9% on a year-over-year basis. Equities research analysts forecast that BioCryst Pharmaceuticals will post -0.69 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BCRX. Bank of New York Mellon Corp boosted its stake in shares of BioCryst Pharmaceuticals by 1.1% during the third quarter. Bank of New York Mellon Corp now owns 767,571 shares of the biotechnology company’s stock valued at $5,434,000 after purchasing an additional 8,087 shares in the last quarter. Arete Wealth Advisors LLC boosted its stake in shares of BioCryst Pharmaceuticals by 64.7% during the third quarter. Arete Wealth Advisors LLC now owns 23,300 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 9,150 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of BioCryst Pharmaceuticals by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 2,388 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Panagora Asset Management Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 6.1% during the third quarter. Panagora Asset Management Inc. now owns 727,480 shares of the biotechnology company’s stock valued at $5,151,000 after purchasing an additional 41,971 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.